AMRI has drafted in Stephen Rossmeisl as senior facilities manager at its aseptic fill and finish facility in Burlington, US.
Prior to joining the firm, Rossmeisl was associate director of facilities operations for Shire.
The firm said he will play a key role in getting the plant back to its “previously robust levels”, following an FDA (US Food and Drug Administration) warning letter in 2009.
Steven Hagen, VP of pharmaceutical development and manufacturing at AMRI said: “Steve will be instrumental in ensuring compliance and overall effectiveness of the facility’s preventive maintenance program and critical environmental monitoring systems, and will lead the planning, oversight and execution of future expansion projects.”
Sample management solutions firm BioStorage Technologies has hired Douglas King as the senior scientific advisor and head of academic scientific research markets.
He will take the helm of the sales and research teams.
Previously he worked for DCL Medical Laboratories, where he was VP and director of business development.
A spokesperson for the firm said King’s appointment was a bid to meet an increased demand for its services, adding: "The advent of molecular and other analytical technologies has resulted in a dramatic increase in the need for biological sample storage.”
AIT Bioscience has named Emilio Córdova as senior VP of business development.
Previously VP of business development at Worldwide Clinical Trials Drug Development Solutions (formerly Cedra Corporation), Córdova will help develop the company’s new services in bioanalytical testing.
He said: “Being involved in a company setting new standards in the field of bioanalytical testing is something that I couldn’t pass up.”
Former Genzyme senior director William Botha has become president Avrio Biopharmaceuticals.
In his new role, Botha will build up the financial structure of the company.
"I am very excited to welcome William to the Avrio team. William brings an important combination of strategic, financial, and operational experience. I am certain that he will play a critical role in the success of our organization," said Assad Kazeminy, CEO and founder .
Chemgen has appointed Debasis Das as the general manager of business development.
Previously, Da was associate director in the medicinal chemistry department at Wuxi AppTec .
In his new role, he will lead the business development department in expanding the firm’s global footpring.
A spokesperson said: “Dr. Das' knowledge gained from supporting a wide range of projects around the world and his overall capabilities to help create innovative solutions to meet customers' expectations will be a great asset to Chemgen Pharma.”